SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine. Its orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company offers orthobiologics products in various forms, such as putties, pastes, strips, and resorbable mesh. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in minimally invasive, complex, deformity, and degenerative procedures. The company was incorporated in 2015 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SPNE
CUSIPN/A
Phone760-727-8399
Debt
Debt-to-Equity Ratio0.04
Current Ratio3.20
Quick Ratio1.48
Price-To-Earnings
Trailing P/E Ratio-6.21
Forward P/E Ratio-8.78
P/E GrowthN/A
Sales & Book Value
Annual Sales$131.81 million
Price / Sales1.91
Cash FlowN/A
Price / CashN/A
Book Value$7.87 per share
Price / Book2.18
Profitability
EPS (Most Recent Fiscal Year)($2.58)
Net Income$-32,110,000.00
Net Margins-21.75%
Return on Equity-27.65%
Return on Assets-21.65%
Miscellaneous
Employees327
Outstanding Shares14,740,000
Market Cap$229.40 million
SeaSpine (NASDAQ:SPNE) Frequently Asked Questions
What is SeaSpine's stock symbol?
SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."
How were SeaSpine's earnings last quarter?
SeaSpine Holdings Corp (NASDAQ:SPNE) issued its earnings results on Monday, July, 30th. The medical equipment provider reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.03. The medical equipment provider earned $36.41 million during the quarter, compared to analysts' expectations of $34.12 million. SeaSpine had a negative net margin of 21.75% and a negative return on equity of 27.65%. View SeaSpine's Earnings History.
When is SeaSpine's next earnings date?
What price target have analysts set for SPNE?
5 brokerages have issued 12 month target prices for SeaSpine's shares. Their predictions range from $15.00 to $23.00. On average, they anticipate SeaSpine's stock price to reach $19.40 in the next year. This suggests a possible upside of 13.3% from the stock's current price. View Analyst Price Targets for SeaSpine.
What is the consensus analysts' recommendation for SeaSpine?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SeaSpine.
What are Wall Street analysts saying about SeaSpine stock?
Here are some recent quotes from research analysts about SeaSpine stock:
- 1. According to Zacks Investment Research, "SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California. " (10/5/2018)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $16 PT on shares of SPNE. SPNE reported solid 2Q results, with revenue of $36.4MM (+6.5%), beating FactSet consensus by $1.8MM and exceeding the company’s expectations of low-single-digit growth. The company continues to execute on its plan to drive market penetration from new products across both spinal implants and orthobiologics and from a more-engaged and increasingly exclusive distributor network. SPNE posted the highest overall and US revenue growth rates since the spin. US spinal implants (+11.5%) stood out as SPNE has now become a share taker in spine. US orthobiologics (+4.0%) was solid, driven by its DBM franchise." (7/30/2018)
- 3. BTIG Research analysts commented, "From New Products Should Set up FY18 SeaSpine ended FY17 with strength in Orthobiologics driving upside in the quarter. Revenue of $34.0M exceeded BTIG/Consensus original expectations of $33.2M. Guidance was maintained ($135M-$139M) but mgmt. provided further clarity on the cadence of revenue throughout the year. SPNE has been filling out its product portfolio with a variety of unique orthobiologic products which we believe should help to bolster growth. That said, the impact of these products will be felt in 2H18 where growth should approach double digits. In addition with recent added capital from a completed ATM, SPNE has the fire power to increase instrument sets in the field which should help the hardware business as well. Net, net we view the set-up for SPNE as attractive in FY18 as new products improve growth, instrument sets support distributors, and valuation remains reasonable. Gross margins a standout. GMs of 63.3% were well ahead of our expectations and up ~460bps from the year ago quarter. Mgmt. is beginning to get leverage from its Irvine manufacturing facility as newer products comprise a larger portion of rev and can be manufactured at higher margins. FY18 GM guidance was set at 61%- 62%." (3/2/2018)
Who are some of SeaSpine's key competitors?
Some companies that are related to SeaSpine include Intersect ENT (XENT), AngioDynamics (ANGO), LeMaitre Vascular (LMAT), MiMedx Group (MDXG), Anika Therapeutics (ANIK), Neuronetics (STIM), Antares Pharma (ATRS), Inovio Pharmaceuticals (INO), Orthopediatrics (KIDS), Liquidia Technologies (LQDA), GenMark Diagnostics (GNMK), Cytosorbents (CTSO), Iradimed (IRMD), Accuray (ARAY) and Utah Medical Products (UTMD).
Who are SeaSpine's key executives?
SeaSpine's management team includes the folowing people:
- Mr. Keith C. Valentine, Pres, CEO & Director (Age 50)
- Mr. John J. Bostjancic, Sr. VP, CFO & Treasurer (Age 47)
- Mr. Patrick L. Keran, VP, Gen. Counsel & Corp. Sec. (Age 46)
- Carrie Mendivil, Head of Investor Relations
- Mr. John J. Winge, VP of Sales (Age 51)
How do I buy shares of SeaSpine?
Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SeaSpine's stock price today?
One share of SPNE stock can currently be purchased for approximately $17.12.
How big of a company is SeaSpine?
SeaSpine has a market capitalization of $229.40 million and generates $131.81 million in revenue each year. The medical equipment provider earns $-32,110,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis. SeaSpine employs 327 workers across the globe.
What is SeaSpine's official website?
How can I contact SeaSpine?
SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-727-8399 or via email at [email protected]
MarketBeat Community Rating for SeaSpine (NASDAQ SPNE)
MarketBeat's community ratings are surveys of what our community members think about SeaSpine and other stocks. Vote "Outperform" if you believe SPNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
